Patients receiving methadone were required to attend a clinic daily to obtain medication following regulations regarding methadone dispensing and thus were more regularly in contact with the clinic personnel, which likely enhanced treatment engagement. Conversely, buprenorphine patients were not required to attend the clinic daily, given the nature of buprenorphine self administration without supervision. Another explanation is that methadone treatment was more accessible to this group of individuals who were largely impoverished. At the end of the follow-up, more than 5 years after baseline, participants with BPD had significantly more heroin and other opioid use in the past 30-days. This finding further supports the claim that some patients with OUD and comorbid psychiatric disorders may have higher rates of opioid use due to their greater psychiatric symptom severity . Consistent with previous studies , patients with OUD and comorbid psychiatric disorders reported poor functioning across multiple domains. Numerous significant group differences in components of ASI composite scores, BSI scale scores, SF-36 physical and mental component summary scores indicated higher problem severity across multiple problem areas in patients with OUD and different comorbid psychiatric disorders. Based on severity, participants with BPD had the poorest functional outcomes. Psychiatric treatment for patients with OUD can be combined with OUD pharmacotherapy and self-help groups. Since the 1970s and 80 s,cannabis grow set up a number of studies demonstrated that psychotherapy can be used effectively with individuals with SUDs . To reduce healthcare costs, however, support was reduced for these psychiatrically focused treatments.
These findings point to an unmet need for medication and psychosocial therapies for patients with OUD and psychiatric comorbidity. This study has several limitations. First, we assessed the type of psychiatric disorders at follow-up Visit 2. Although the question about the history of psychiatric disorders was included at treatment entry , the pre-existing diagnosis patterns according to objective measures and the temporal relationship between OUD and psychiatric disorders are unknown. Second, attrition analysis showed that female participants had a higher follow-up rate, which might be over represented in this study, but the rates of treatment engagement in the present study were similar to an 11-year follow-up of the Australian Treatment Outcome Study . Third, results are based on a sample of individuals treated for OUD in community-based, federally regulated OTP clinics, and thus findings may have limited applicability to patients treated in primary care clinics or other settings. Fourth, we did not include sedative use , which is common in individuals with OUD and did not collect information about participants’ treatment for mental health disorders, both of which could have impacted treatment outcomes. Finally, substance use and treatment participation were self-reported and may be subject to recall bias. As for study strengths, this secondary analysis was conducted with a relatively large sample derived from a multi-site clinical trial and a follow-up prospective longitudinal study with a long duration to assess associations between OUD pharmacotherapy treatment outcomes and co-occurring psychiatric conditions. Our study sample has a similar rate of psychiatric disorders as has been reported in nationally representative data . Electronic -cigarettes are drug delivery devices primarily used for the inhalation of nicotine and marijuana, in the form of tetracannabinoids . The modern e-cigarette was invented in 2003, entered the global market in 2007, and has rapidly become popular across the world. There are many types of e-cigarettes, from cig-a-likes to vape pens and box Mods to pod-devices, but they all involve heating and aerosolization of e-liquids .
The base ingredients of e-liquids, nicotine, propylene glycol and glycerin, have an unappealing flavor on their own such that chemical flavorants are added to >99% of e-liquids to increase the appeal to users. Use patterns of electronic -cigarettes and vaping devices differ greatly across age groups. Adults most commonly pick up vaping in the setting of conventional cigarette smoking, either adding it into their smoking practice or switching to e-cigarettes as a means to stop smoking. While 3.2% of all adults use ecigarettes, the rates are much higher in young adults 18-24 years-old, of whom 7.6% vape, and higher still in high school students, of whom 27.5% have used a vaping device within the past month. Sadly, middle school students as young as age 11 also have high rates of e-cigarettes use. While adult e-cigarette users are most often active smokers or ex-smokers, 44.3% of adolescents and young adults were never smokers prior to e-cigarette use. Of concern, it has been shown that e-cigarette use in never smokers leads to higher initiation of cigarette smoking, up to four-fold. A great deal of research to date has been focused on comparing e-cigarette use to cigarette smoking to assess the potential benefit of switching from smoking to vaping as a form of harm reduction, while less focus has been on the health effects of vaping in non-smokers, for whom the rates of vaping continue to rise, particularly in the youth. E-cigarettes have been marketed as a form of harm reduction from traditional cigarette smoking, but neither the safety nor the efficacy of these devices has been established, and little is known about the short and long term pulmonary and systemic health effects. This review focuses on the known and unknown toxins contained in e-cigarette aerosols, lung diseases induced by vaping, and the predicted long-term consequences of e-cigarette use. Particular attention is given to the e-cigarette or vaping product use-associated lung injury epidemic that began in 2019 and is ongoing. E-cigarettes are devices composed of a power source, heating element, and liquid reservoir that heat and aerosolize e-liquids to make vapor that is inhaled into the lungs in a process known as vaping.
E-liquids are most often composed of 1) Addictive substances such as nicotine and/or tetrahydrocannabinol , 2) Flavorings, and 3) Solvents . There are many types of vaping devices, but the most frequently used include pod vapes, box mods, and vape pens . The pod devices were widely popularized by the company Juul, which developed its sleek device to look like a flash-drive that quickly became the most profitable e-cigarette by the end of 2017. The e-liquids in Juul pods contain high concentrations of the more rapidly absorbed nicotinic salts complexed with benzoic acid, compared to free based nicotine,outdoor cannabis grow thus increasing the addictive potential and toxicity. Given that nicotine exposure influences long-term molecular, biochemical, and functional changes in the adolescent brain, it is not surprising that teens who vape are at increased risk of subsequent use of traditional cigarettes, marijuana, opioids, and other illicit drugs with addictive potential. THC also induces alterations in reward networks in the adolescent brain, which increases risk for future drug use, and regular cannabis users of any age have poorer neurocognitive functioning and functional brain alterations relative to nonusers. Although vaping devices are not an approved nicotine replacement therapy, the Federal Drug Administration has allowed e-cigarette manufacturers to design e-liquids using components that have been ”generally recognized as safe” . Compounds that have GRAS status are only assessed as safe to ingest via the gastrointestinal tract, or put on the skin. Thus, the vast majority of compounds with this designation have not been tested for safety via the inhalation route. There are thousands of different flavoring ingredients used, and thermal decomposition of propylene glycol, glycerol, and flavoring agents result in the production of toxic aldehydes at levels that exceed occupational safety standards. Chemical flavorings such as diacetyl and 2,3-pentanedione, present in many e-liquids, have been found to induce transcriptomic changes that disrupt cilia function in human airway epithelium, impairing mucociliary clearance. Cumulative exposure to diacetyl is well known to be associated with the development of the irreversible airway fibrosing disorder bronchiolitis obliterans , with the term “popcorn lung” used when referring to BO described in microwave popcorn factory workers. Other toxins found in e-cigarette vapor with inhalant and systemic toxicities including terpenes, acrylonitrile, formaldehyde, crotonaldehyde, propylene oxide, acrylamide, and heavy metals. None of these products are currently regulated, but there is even greater cause for concern regarding the inhalant toxicity for the components in “black market” or counterfeit e-liquids and devices as well modified devices. Finally, microbial toxins may contaminate vaping devices even prior to use.
One study tested the leading U.S. pod vape and found that 81% of devices contained B-D-glucan, a fungal cell wall marker, and 23% contained endotoxin, found in the outer wall of gram-negative bacteria. Both of these microbial contaminants are associated with asthma and hypersensitivity pneumonitis. E-cigarettes have been marketed as a form of harm reduction from traditional cigarette smoking, but neither the safety nor the efficacy of these devices has been established, and little is known about the short and long term pulmonary and systemic health effects. There have been increasing reports in the literature of negative pulmonary effects with the recent epidemic of e-cigarette or vaping product use-associated lung injury being the most immediately concerning. Reports of the development of chronic respiratory symptoms, increased asthma morbidity, and the development of diffuse lung disease in both adolescents and adults highlight significant pulmonary toxicity and compel further research. E-cigarette users are more likely to report chronic respiratory symptoms and conditions in both adolescents and adults. In a large study from Hong Kong of 45,000 adolescents who vaped in the previous month reported chronic cough or phlegm production with increased odds. In a smaller study of 2,000 high school students in Southern California, past and current vaping was associated with a nearly two-fold increase in the risk of chronic bronchitis symptoms. In a longitudinal analysis of adults in the Population Assessment of Tobacco and Health Waves 1, 2, and 3 with data collected from 2013-2016, a significant association between former and current use at Wave 1 and incident respiratory disease at Waves 2 or 3 was demonstrated, controlling for combustible tobacco smoking and other demographic, and clinical variables. In this study, dual use of cigarettes and ecigarettes had increased odds of developing respiratory disease of 3.30 compared with a never smoker/vaper. Among asthmatic patients, primary e-cigarette use and secondhand exposure confers increased morbidity. Interestingly, vaping is more popular among asthmatic teenagers as compared to their non-asthmatic peers. The reason for this observation is unclear, but may be related to the commonly held belief that vaping is safer than smoking cigarettes. Among adult never cigarette smokers, current e-cigarette use was associated with 39% higher odds of self-reported asthma compared to never e-cigarette users. In South Korea, vaping in high school students was associated with increased odds of being diagnosed with asthma and more missed days of school secondary to asthma. The Florida Youth Tobacco Survey showed that past-30-day e-cigarette use was associated with having an asthma attack in the past 12 months among high school participants with asthma. This survey later revealed that 33% of 11- to 17-year-olds with asthma had secondhand ecigarette exposure, and this exposure was associated with increased risk of asthma exacerbation. There are also case reports of two adolescent asthmatic e-cigarette users who presented with life-threatening status asthmaticus requiring VV-ECMO. This may indicate increased risk for more severe exacerbations among asthmatic teens who are vaping. In addition, EVALI cases from both the Illinois and Wisconsin cohort and Rochester cohort reported higher- than expected rate of EVALI in asthmatics.There have been multiple case reports of different types of severe and life-threatening diffuse lung disease in patients using vaping products including hypersensitivity pneumonitis, eosinophilic pneumonitis, diffuse alveolar hemorrhage, lipoid pneumonia and bronchiolitis. These case reports demonstrate that there is undeniable harm associated with vaping even before decades of use. Among patients with EVALI, pathology results included findings consistent with acute lung injury including acute fibrinous pneumonitis, diffuse alveolar damage, and organizing pneumonia. Taken together these pathological findings indicate that severe lung injury in multiple different patterns can occur in the setting of vaping. Although the mechanism of injury in these patients is currently unknown, it is presumed that there are both product and host related factors contributing to lung injury. Given that multiple components of vaping products can cause pulmonary toxicity, it is unlikely that there is only one chemical component leading to these diverse patterns of toxic lung injury. Beyond the scope of this review are systemic toxicities as well as trauma due to explosions, thermal injuries and acute intoxications including ingestion of e-liquids.